BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15503293)

  • 1. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy.
    Broxson EH; Dole M; Wong R; Laya BF; Stork L
    Pediatr Blood Cancer; 2005 Mar; 44(3):226-31. PubMed ID: 15503293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
    Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
    Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience.
    Ravikumara M; Hill FG; Wilson DC; Gillett PM; Thomas A; Brown R; Darbyshire PJ; McKiernan PJ
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):535-8. PubMed ID: 16707977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
    Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
    Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A; Teml A; Reinisch W; Ulbrich G; Wrba F; Homoncik M; Gangl A; Peck-Radosavljevic M; Vogelsang H
    Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
    Lancaster DL; Patel N; Lennard L; Lilleyman JS
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term risk of portal hypertension and related complications in children treated with 6-thioguanine for acute lymphoblastic leukemia: A single-center experience.
    Roy Moulik N; M Taj M
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28233441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of children with 6-thioguanine-related chronic hepatoxicity following treatment for acute lymphoblastic leukaemia.
    Rawat D; Gillett PM; Devadason D; Wilson DC; McKiernan PJ
    J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):478-9. PubMed ID: 21701407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
    Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
    Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory predictors of esophageal varices in children and adolescents with portal hypertension syndrome.
    Fagundes ED; Ferreira AR; Roquete ML; Penna FJ; Goulart EM; Figueiredo Filho PP; Bittencourt PF; Carvalho SD; Albuquerque W
    J Pediatr Gastroenterol Nutr; 2008 Feb; 46(2):178-83. PubMed ID: 18223377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
    Kitchen BJ; Balis FM; Poplack DG; O'Brien M; Craig CE; Adamson PC
    Clin Cancer Res; 1997 May; 3(5):713-7. PubMed ID: 9815740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy.
    Warren DJ; Andersen A; Slørdal L
    Cancer Res; 1995 Apr; 55(8):1670-4. PubMed ID: 7712473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.
    De Bruyne R; Portmann B; Samyn M; Bansal S; Knisely A; Mieli-Vergani G; Dhawan A
    J Hepatol; 2006 Feb; 44(2):407-10. PubMed ID: 16226335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
    Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
    Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.